Algert Global LLC held its stake in shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,924 shares of the biopharmaceutical company’s stock at the end of the second quarter. Algert Global LLC’s holdings in BioSpecifics Technologies Corp were worth $392,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the company. Wedge Capital Management L L P NC purchased a new position in shares of BioSpecifics Technologies Corp during the first quarter worth approximately $2,093,000. Alliancebernstein L.P. raised its position in shares of BioSpecifics Technologies Corp by 401.8% in the first quarter. Alliancebernstein L.P. now owns 40,820 shares of the biopharmaceutical company’s stock worth $2,237,000 after buying an additional 32,685 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of BioSpecifics Technologies Corp by 15.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 229,340 shares of the biopharmaceutical company’s stock worth $12,774,000 after buying an additional 30,210 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of BioSpecifics Technologies Corp by 6.0% in the first quarter. Renaissance Technologies LLC now owns 352,627 shares of the biopharmaceutical company’s stock worth $19,324,000 after buying an additional 19,881 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of BioSpecifics Technologies Corp by 35.5% in the first quarter. AQR Capital Management LLC now owns 74,159 shares of the biopharmaceutical company’s stock worth $4,064,000 after buying an additional 19,437 shares in the last quarter. Hedge funds and other institutional investors own 54.97% of the company’s stock.

BioSpecifics Technologies Corp (NASDAQ BSTC) opened at 45.21 on Friday. The firm has a 50-day moving average of $49.59 and a 200-day moving average of $51.88. BioSpecifics Technologies Corp has a one year low of $35.79 and a one year high of $58.79. The firm has a market cap of $323.97 million, a price-to-earnings ratio of 27.74 and a beta of 1.76.

TRADEMARK VIOLATION WARNING: “Algert Global LLC Has $392,000 Position in BioSpecifics Technologies Corp (NASDAQ:BSTC)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/12/algert-global-llc-has-392000-position-in-biospecifics-technologies-corp-nasdaqbstc.html.

BSTC has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Monday, May 15th. HC Wainwright set a $72.00 price objective on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday. Finally, BidaskClub lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp (NASDAQ:BSTC).

Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.